MAIA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

MA

Mkt Cap

$67.6M

Volume

361.03K

Next Earnings

November 6th

Loading chart

MA

MAIAMAIA Biotechnology, Inc.

MAIA

Pay with—

Available Balance0.00

MA

Mkt Cap

$69.2M

Volume

361.03K

Next Earnings

November 6th

Chart Financials Earnings News About Insider Filings

Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)MAIA Biotechnology completed a $30 million equity raise and announced 2026 strategic milestones including Phase 3 trial progress for its ateganosine cancer therapy. The company secured FDA Fast Track designation and reported positive Phase 2 data showing median PFS of 5.6 months and OS of 17.8 months. Diamond Equity Research maintains a $10.27 per share valuation based on successful execution of clinical programs.GlobeNewswire Inc. · Mar 5, 2026

MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common StockMAIA Biotechnology, Inc. announced the successful closing of an underwritten public offering of 20 million shares at $1.50 per share, raising $30 million in gross proceeds. The offering was led by healthcare-dedicated investors alongside existing shareholders. The company plans to use net proceeds for clinical trials and general corporate purposes.GlobeNewswire Inc. · Mar 4, 2026

MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common StockMAIA Biotechnology priced an underwritten public offering of 20 million shares at $1.50 per share, raising $30 million in gross proceeds. The offering was led by healthcare-dedicated investors alongside existing shareholders. Net proceeds will be used for clinical trials and general corporate purposes. The offering is expected to close on March 4, 2026.GlobeNewswire Inc. · Mar 3, 2026

MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded WarrantsMAIA Biotechnology announced an underwritten public offering of common stock and pre-funded warrants, with Konik Capital Partners LLC serving as sole book-running manager. The company intends to use net proceeds for clinical trials and general corporate purposes. MAIA's lead program, ateganosine (THIO), is a potential first-in-class cancer telomere targeting agent in clinical development for NSCLC treatment.GlobeNewswire Inc. · Mar 2, 2026

$207B Market Shift: The Race for Fast Track Approval in OncologyThe FDA has accelerated oncology drug approvals with over 50 approvals in 2025 and increased expedited designations in 2026. Multiple biotech companies are advancing cancer treatments through Fast Track and Breakthrough Therapy designations, targeting high-unmet-need solid tumors. Key developments include Oncolytics' pelareorep showing significant survival benefits in colorectal cancer, Relay's zovegalisib receiving Breakthrough designation for breast cancer, MAIA's ateganosine advancing in lung cancer, Zai Lab's AUGTYRO approval in China, and Arrivent's firmonertinib entering pivotal Phase 3 trials for NSCLC.Benzinga · Feb 5, 2026

MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting ApproachMAIA Biotechnology is developing ateganosine, a novel telomere-targeting cancer therapy for non-small cell lung cancer patients who do not respond to existing treatments, with potential to address a significant unmet medical need.GlobeNewswire Inc. · Dec 10, 2025

MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients - BenzingaMAIA Biotechnology's lung cancer drug THIO, sequenced with Regeneron's cemiplimab, has shown promising long-term benefits in advanced non-small-cell-lung-cancer patients who failed previous treatments. The treatment has been well-tolerated with lower toxicity than standard-of-care, and some patients have continued the treatment for over 12 months, demonstrating safety, efficacy, and ongoing benefits.Benzinga · Jul 23, 2024

MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific AdvisorCHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB).GlobeNewswire Inc. · Feb 27, 2024

MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung CancerCHICAGO, IL, Feb. 22, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that enrollment is now complete in its Phase 2 THIO-101 go-to-market clinical trial evaluating THIO sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in advanced non-small cell lung cancer (NSCLC).GlobeNewswire Inc. · Feb 22, 2024

MAIA Soars 20% on Interim Results From Lung Cancer StudyMAIA Biotechnology (MAIA) reports updated results from a mid-stage study. Patients treated with its lead drug achieved disease control rates that were well-sustained compared with previous scans.Zacks Investment Research · Jan 18, 2024

to start trading

MA

MAIAMAIA Biotechnology, Inc.

MAIA

Pay with—

Available Balance0.00

Your PositionYou don't own any MAIA yet.

Related Tickers

Earnings